Answers are grounded in this paper and cite their sources.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits and harms of belimumab in systematic lupus erythematosus (SLE).
No takes yet. Share an insight, caveat, or question.
Singh et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: